The foramen ovale is a door-like opening of the interatrial septum framed by the septum primum and septum secundum. In utero it serves as a pathway for oxygenated blood to shunt from the right to the left atrium, thereby bypassing the nonfunctional lungs.
After birth a right-to-left shunt is undesirable and the foramen ovale closes. However, in a quarter of the population no permanent closure occurs, and the patent foramen ovale (PFO) may allow particulate or chemical material to pass from the venous to the arterial circulation, especially during increased right atrial pressure (e.g., Valsalva manoeuvre). A PFO has been associated with cryptogenic stroke, myocardial infarction, migraines, sleep apnoea, platypnoea-orthodeoxia, diving-associated decompression illness and high-altitude pulmonary oedema. Nevertheless, the majority of humans with a PFO live without experiencing a PFO-related medical condition [1] . Therefore, the PFO does not qualify as a screening target in the general population [2] and primary prophylactic PFO closure in asymptomatic individuals is not recommended.
Stroke is one of the most feared and devastating health disorders. One third of strokes are so-called cryptogenic because no apparent cause is found. The prevalence of a PFO in patients suffering a cryptogenic stroke is higher than in patients with known stroke causes [3, 4] . Nonetheless, in a large number of patients with cryptogenic stroke, no PFO is found [4] . Given the high background prevalence of PFO in the general population, many PFOs detected in patients with cryptogenic stroke are incidental. However, PFO patients who suffered a paradoxical embolism may represent a higher risk cohort and may benefit more from PFO closure compared with medical management, especially when an atrial septal aneurysm or large shunt is present.
In the 1970s and 1980s percutaneous closure of interatrial connections was developed. On the basis of mostly nonrandomised, observational data, PFO clo- analysis of this randomised trial showed that PFO closure reduced the relative risk of recurrent cryptogenic stroke by 70% compared with medical therapy (1.5 to 4.3%; p = 0.004). As paradoxical embolism is excluded after successful PFO closure and conservatively treated patients face a persistently increased bleeding risk due to continuous antithrombotic medication, it is expected that event-curves for safety and efficacy will continue to separate over the years. However, with increasing age the susceptibility to noncryptogenic stroke increases. Therefore, during long-term follow-up the effect of PFO closure becomes blurred by events unrelated to the PFO. In this setting, paradoxical embolism has to be discriminated from events caused by atherosclerotic plaque rupture, which becomes more prevalent with age. The scrutiny of scientific researchers is mandatory to dissect the various causes of ischaemia in an aging cohort and tease out the group that may benefit from PFO closure by sound analyses and adequately powered randomised con- 
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For these reasons, the European Union is paying a lot of attention to the harmonisation of medical education in Europe and to the safeguard professional standards in the field of medicine [1] . In order to achieve this goal, the delivery of harmonised high-standard This electronic tool is ESCeL (ESC e-Learning).
The ESCeL project structure
The ESCeL platform was developed with a modular structure ( fig. 1 ) that would enable the platform to be The patient safety module is used by the trainee to log each month complications they have encountered. Therefore, the contribution of all these stakeholders is critical for the platform to work properly at the national level.
In terms of workflow ( fig. 2 ), everything starts with the decision of the country (national society, national accreditation authority) to participate in the project. As soon as the national group informs the ESC that they want to participate, the ESC will ask the national group to provide a list of training hospitals, training directors and local trainers in this country. Once this information is registered, trainees from this country can start to enrol in the ESCeL platform where they will find this information. After trainee enrolment, the notice is sent automatically to the national society or national accreditation authority for verification. This is important to make sure that the person who has enrolled is legally entitled to undertake training, and to check if the training hospital, training direc tor and local trainer are able to deliver training to the trainee.
Only after sign-off of this national institution can the trainee start using ESCeL for training purposes. This is a critical contribution of the national group, and can only be performed at the national level.
The platform has two special features that are useful.
One is a set of tracking rules that ensure that all im- how they can perform better in the future. This will be valuable for the trainee and will contribute to the progressive harmonisation of training across Europe and beyond Europe.
Finally, the platform is prepared to deal with interruptions of training due to sick leave, pregnancy or military service. It is also able to integrate training periods in different institutions, when trainees seek specific training in some highly specialised techniques.
ESCeL project, current situation
Since the official launch of the project in 2012, the ES- 
The news in 2015
The ESCeL platform project is an ongoing project that is continuously improving and adapting to changes and 
Conclusion
There is a large heterogeneity of cardiology training and education in European countries. Taking into consideration the reality of the free movement of doctors and patients across borders, the cardiology community feels a strong need for harmonisation of the training and education of European health professionals.
The ESC has already produced the standards, and recently developed the tool to deliver these standards:
the ESCeL platform. This project is currently on its road of success. A challenge for the future is the possibility of massive participation of professionals, in the number of thousands, not hundreds. Although this project raises a lot of questions and challenges it also opens a wealth of new possibilities for the future of our profession and particularly to the delivery of a high standard of care to our cardiovascular patients.
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Potential perioperative risks
The main concerns when using cautery in a patient with a CIED is that it may inhibit pacing in a pace- When using an argon beam coagulation system, reprogramming of the pacemaker in a dependent patient should be considered, since experience is still limited [1] .
Of course, other consequences during surgery can impair the functionality of the device (e.g., physical damage to the leads, increase of pacing thresholds with loss of capture, increase of ICD defibrillation threshold owing to a perioperative pneumothorax, etc.).
Principle of magnet use
CIEDs possess a reed switch which is activated when a magnetic field is applied. In short, the reed switch consists of two magnetic metal strips, that are usually separated, in a glass capsule. The magnetic field will bring these two strips together, which results in a sudden voltage change sensed by the sensing amplifier that will trigger programmed functions such as asynchronous pacing [3] . Newer devices that are designed to be magnetic resonance imaging-safe are equipped with
Hall-effect sensor switches, which trigger an electronic switch when activated by a magnetic field. The application of a magnet switches the programmed mode to an asynchronous mode and inactivates the rate response feature. Biotronik pacemakers are an exception in that in the default "auto" setting they will pace asynchronously for 10 beats only and then revert to the programmed synchronised mode.
Implantable cardioverter defibrillators (table 3)
Generally, magnet application suspends antitachycardia therapy without any effect on the pacing mode.
Sorin ICDs are an exception and will pace with the magnet rate. This means that the pacemaker part continues to function in the programmed synchronous mode, including rate responsiveness. Approximately 25% of ICD patients also require some kind of antibradycardia pacing.
Boston Scientific ICD can respond in a complex fashion. Older devices (PRIZM and VITALITY 1 families)
have the "change the mode with magnet" feature that can be programmed on. In that case magnet placement can permanently switch antitachycardia detection and therapy off. In order to reactivate it, the magnet has to be reapplied for >30 seconds. In the more recent Boston Scientific models, the "change the mode with magnet" feature is absent and these ICDs behave like the others. If in doubt, interrogating the Boston Scientific defibrillators postoperatively is strongly recommended.
Minimal preoperative care
Before surgery one must ascertain whether the patient carries a CIED and if so which type. Usually, the patient presents with a pacemaker/ICD identification card that contains all important information. In the case of an emergency or other circumstances preventing the patient from providing this information, a scar in the left or right pectoral region should be sought. In most instances, the device can be palpated. The minimal information that has to be obtained before surgery is whether the patient carries a pacemaker or an ICD. This is important since the response to magnet application differs and may become an issue in a pacemakerdependent patient. This information can easily be 
Intraoperative care
In all patients with an implanted CIED, the anaesthetic workplace must be equipped with a defibrillator with pacing capability. In cases where the patient is completely pacer dependent, or where the ICD functionality will be switched off and where there is no unrestricted access to the patient's torso, defibrillation/ pacing pad must be installed and connected to the external de fibrillator device preoperatively.
Pacemakers
The CIED should be accessible for magnet application. In suspected or known pacemaker dependency, a magnet should be positioned over the generator, which results in asynchronous pacing in a VOO, VDO or DOO mode at a manufacturer-specific rate (table 1) . Alternatively, the magnet may be applied only if inhibition by cautery is really observed (provided the device is read- ily accessible), particularly in operations below the umbilicus or a distance of >15 cm to the device [4] . In the default setting, which will be encountered in the overwhelming majority of CIED carriers, Biotronik pacemakers will revert to a synchronous mode after 10 beats. Should the need arise, the magnet may be removed and reapplied, which will render the device asynchronous for the following 10 beats.
PACEMAKERS (PM)
In very rare cases, asynchronous pacing can induce ventricular fibrillation by pacing in the vulnerable period of the T-wave. Therefore, patients need to be monitored and an external defibrillator must be present. In clinical practice, this rarely causes problems when some principles regarding cautery are kept in mind (see above).
Implantable cardioverter defibrillators
Regarding ICD carriers a magnet should always be securely applied in order to disable the antitachycardia functions. In fact, we recommend magnet positioning over reprogramming since the device will always immediately function as programmed after magnet removal. There is an abundance of clinical anecdotes of fatal and near-fatal events linked to failure to restore appropriate device settings [5] .
In a pacemaker-dependent ICD patient, however, the device has to be reprogrammed to an asynchronous pacing mode and the tachycardia therapies have to be 
Postoperative care
After the removal of the magnet, the programmed set- 
Conclusion
The vast majority of patients with a CIED who undergo In patients with presumed paradoxical embolism, secondary prevention remains a matter of debate.
Patients with cryptogenic stroke related to PFO are at risk for recurrence despite medical treatment, with yearly recurrence rates ranging from 0.6-12% [6, 7] , a risk that may be particularly pronounced in patients with PFO and associated ASA [6, 8] . Nonrandomised data suggest the superiority of percutaneous PFO closure for secondary prevention of paradoxical embolism as compared with medical treatment alone [7, [9] [10] [11] . However, three randomised studies failed to confirm these results [12] [13] [14] . As the protocols of all three trials over estimated the incidence of recurrent events in both groups, data on long-term clinical
Summary
Background: Percutaneous patent foramen ovale (PFO) closure has been shown to be safe and feasible with a variety of devices, and its clinical efficacy appears favourable compared with medical treatment alone. However, long-term follow-up remains largely unknown. We report the late clinical results of our early experience with one of the first commercially available devices, the Sideris Buttoned Occluder.
Methods: Thirty-two patients (age 50 ± 12 years; 63% male; 28% atrial septal aneurysm) underwent PFO closure using the Sideris Occluder for secondary prevention of presumed paradoxical embolism.
Results: There were four procedural complications (13%), including two embolisations of the counteroccluder of the device with successful percutaneous removal in both cases, and one arteriovenous fistula requiring surgical repair. The implantation procedure failed in one patient (3%) because of laceration of the femoral artery, with ensuing retroperitoneal haematoma requiring surgical revision. None of these complications had long-term sequelae. Contrast transoesophageal echocardiography at 6 months showed complete closure in 55% of cases, and a minimal, moderate, or large residual shunt in 28%, 7%, and 10%, respectively. During a mean follow-up period of 12.3 ± 2.6 years (median 13 years; total 378 patient-years), one death, two ischaemic strokes, two transient ischaemic attacks (TIAs), and one peripheral embolism occurred. Survival free from recurrent ischaemic stroke, TIA, or peripheral embolism was 97% at 1 year, 90% at 5 years, and 84% at 10 years. There was one incident of atrial fibrillation.
Introduction
The association of patent foramen ovale (PFO) with cryptogenic stroke, independently reported by Lechat [1] and Webster [2] in 1988, has been repeatedly confirmed [3, 4] . This observation has been extended to [2] . In order to demonstrate unequivocally the presence of a PFO, care was taken to document the actual passage of contrast bubbles through the rent, but this was not possible in all cases.
Sideris Buttoned Occluder
The SBO ( fig. 1) at the time was a polyester patch on a nitinol cross frame in the left atrium, retained by a polyester coated wire in the right atrium. It could be constrained within an 11 French (Fr) delivery system. The retaining wire was pushed over a nylon thread fed through a central hole in the polyester coat. The thread featured a knot which prevented disengagement of the retaining wire, once it was advanced over the knot.
Percutaneous PFO closure
The interventions were performed under local anaesthesia and fluoroscopic guidance [16] . Intraprocedural guidance by TOE [17] [18] [19] or intracardiac echocardiography [20, 21] was not used in any case. However, all patients had undergone contrast TOE for initial diagnosis of PFO prior to the intervention. The transseptal sheath was then used for a final contrast medium injection. The contrast can be followed through to the levophase to delineate the left atrial contour and device placement also. Finally, the sheath was removed and haemostasis achieved by manual compression. Patients were released to full physical activity as early as a few hours after the procedure. Transthoracic contrast echocardiography was performed before discharge in order to document correct and stable device position. Acetylsalicylic acid (100 mg) was prescribed once daily for 6 months for anti thrombotic protection.
As reported in previous publications by our group, we performed systematic coronary angiography in patients undergoing percutaneous PFO closure aged >50 in males and >60 in females. In this study, a rather high proportion of the examined patients (29%) presented with unsuspected coronary artery disease, justifying incidental coronary angiography in selected patients. Predictors were the age as well as the presence of conventional cardiovascular risk factors [22] .
Follow-up evaluation
The outcome following the intervention was prospectively assessed for up to 15 years. A contrast TOE was repeated 6 months after percutaneous PFO closure.
Thereafter, patients underwent structured telephone interviews, addressing recurrent embolic events, device related problems, and health status at regular intervals. Initial follow-up information was available for all patients, but two patients (6%) were eventually lost to follow-up.
Death, and recurrent ischaemic stroke, TIA, or peripheral embolism were considered endpoints. Patients with suspected recurrent cerebrovascular events were re-examined by a neurologist, and a new imaging study of the brain was performed.
Statistical analysis
An intention-to-treat analysis was performed considering all patients selected for implantation of a SBO during the study period, including the patient in whom the implantation failed. 
Results

In-hospital outcome
Discussion
We report the late clinical follow-up of a cohort of 32 patients with presumed paradoxical embolism treated at a single centre using the SBO, mainly with regards to the follow-up duration of over 10 years.
These data represent the early technical experience in the field of percutaneous PFO closure. The SBO, which was one of the first commercially available devices, has been modified since, but is no longer used at our centre because of the availability of more versatile, effective, and easier to use devices. However, despite the high procedural complication rate of 13%, and the fact that complete PFO closure could be achieved in 55% of cases only, the long-term clinical efficacy of percutaneous PFO closure turned out to be good.
In the literature, the reported success rates of percutaneous PFO closure varies between 90-100%, with complication rates between 0-10%. Complete PFO closure is reported in 51-100% of patients [23] , depending on device type and methodology used (transcranial Doppler, transoesophageal or transthoracic echocardiography), and the yearly recurrence rates of ischaemic strokes and transient ischaemic attacks (TIAs) vary between 0-5% [7] .
Important differences were observed between the devices used [24] [25] [26] . Initial device-related complications inflicted by large delivery systems, device dislodgement and embolisation, structural failure, thrombus formation [27] , and inability to reposition or remove the device were reduced by improvements in device design. Anatomical and physiological differences between PFOs and atrial septal defects led to the development of devices specifically designed for percutaneous PFO closure. Current devices for percutaneous PFO closure, such as the Amplatzer PFO Occluder, achieve complete PFO occlusion in >90% of cases with complication rates <1% and yearly recurrence rates <1% [23] . This improvement in device performance is likely to positively impact clinical outcome.
During long-term follow-up of up to 15 years, the risk of stroke or death after transcatheter treatment of PFO with or without associated ASA was <1% per year. The low recurrence rate corresponds with the long-term outcome (mean follow-up of 9.2 ± 3.0 years) previously described by our group [28] and compares favourably with medical treatment [11, 29] .
However, the three randomised trials completed so far, concern. The rate of recurrent events 10 years after percutaneous PFO closure is low.
Limitations
Since both PFO and cryptogenic stroke are prevalent conditions, they may coexist without causal relationship in many patients. Percutaneous PFO closure in patients with falsely PFO-related strokes will not influence recurrent embolic events, a circumstance likely to contribute to the small recurrence rate despite successful PFO closure in our and other series. Nonetheless, these patients will be protected against true paradoxical embolism. It has to be emphasised that the true thera peutic efficacy of percutaneous PFO closure as adjunct or alternative to medical treatment can only be ascertained by randomised studies.
Remark
The 
Discussion
Rivaroxaban is an oral inhibitor that binds directly to factor Xa. It is approved for treatment of deep venous thrombosis, pulmonary embolism and nonvalvular atrial fibrillation [5, 7, 12] .
A Japanese team published three cases of left atrial appendage thrombus resolution using rivaroxaban 10 mg/d [13] . Another case report described the growth of a left atrial appendage thrombus despite well-conducted treatment with a VKA, which then disappeared during treatment with rivaroxaban 15 mg/d [14] . To the best of and a small increase in major bleedings [17] .
Risk of bleeding should be utilised in decision-making.
The HAS-BLED score was 1 for this patient, who had normal renal function with a creatinine clearance of 83 ml/ min (1 point because of the concomitant use of antiplatelet agents and oral anticoagulation, i.e., a risk of major bleeding of 1.0-1.5% per year). Based on the above described case reports, where rivaroxaban was the most frequently used molecule and always prescribed once a day (never 15 mg twice daily as for the first 3 weeks of the 
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Six-month follow-up
Sixteen-month follow-up
The patient complained of recurring moderate dyspnoea and pitting leg oedema. NT-proBNP was in- and it was hypothesised that it would positively affect the cardiomyopathy [2] . Unfortunately, a recent paper confirmed that benznidazole significantly reduces se- Pa tients are categorised as low (0 to 6 points), intermediate (7 to 11 points) and high risk (12 to 20 points). The 10-year mortality rates were 10%, 44% and 84%, respectively. Our patient had 18 points and was at high risk.
Unfortunately, benznidazole was found to be unable to stop the progression of the cardiomyopathy in chronic Chagas disease. The long-term prognosis of Chagas cardiomyopathy remains poor. American immigrants with nonischaemic heart disease) [2] . Because Chagas disease is rare in Europe, women at risk for congenital transmission to their infants are rarely screened and in patients cardiac and gastro intestinal pathologies are often diagnosed at a late stage [2] .
Infected European patients
Diagnosis of Chagas disease
The first step for diagnosing Chagas disease is the his- Most infected persons are asymptomatic but are permanently infected [2] [3] [4] [5] [6] [8] [9] [10] . Over decades up to 30% of infected patients develop Chagas cardiomyopathy, which is highly arrhythmogenic [1] [2] [3] [4] [5] [6] [8] [9] [10] . Orally transmitted T. cruzi infection appears to be associated with a higher incidence of myocarditis and death than vectorborne infection [11] .
Complications
Chagas cardiomyopathy is highly arrhythmogenic. cific for Chagas cardiomyopathy but indicate that the heart is affected years before the pathology becomes symptomatic.
Gastrointestinal Chagas disease predominantly affects the oesophagus, colon, or both and results from damage to intramural neurons [2, 8] . It is less frequent than Chagas cardiomyopathy and is more common in Argentina, Bolivia, Chile, Paraguay, Uruguay, and parts of Brazil than in northern South and Central America [2, [8] [9] [10] [11] . It was suggested that this geographic pattern might derive from different genotypes of T. cruzi [2, [11] [12] [13] but, in several studies, no strain differences have been detected between infections with and without gastrointestinal manifestations [8, 13, 14] . 
Pathogenesis
Therapy
Progress has been made in the past 5 years toward improving the treatment of Chagas disease [2] . Rarely
Chagas infection may be recognized in the early phase and the trypanocidal drug benznidazole can be used to reduce the level of parasitaemia of T. cruzi and might be useful to treat acute infections [2] . However, a recent study has demonstrated that therapy with benznidazole has no detectable effects in patients with established Chagas cardiomyopathy [3] . T. cruzi infection remains the most important parasitic disease in South,
Central and North America, with an estimated disease burden (measured by disability-adjusted life-years) that is 7.5 times as great as that of malaria [18] . These facts show the need of an urgent search for a treatment with high efficacy during the chronic phase.
There is no specific cardiac therapy for Chagas cardiomyopathy. The disease is highly arrhythmogenic.
Therefore, bradycardic arrhythmias, AV-and/or bundle-branch blocks and complex ectopic arrhythmias are a proven indication for a pacemaker and/or ICD implan tation. Atrial flutter and/or fibrillation are frequent complications and high-risk patients (assessed with the CHA2-DS2-VASc score) need oral anticoagulation. Congestive heart failure is empirically treated as recommended in modern guidelines [19] . As yet there are no trials on the use of valsartan/sacubitril in Chagas cardiomyopathy, but our personal opinion is to use this therapy when Chagas patients develop clear signs of heart failure.
The therapy of gastrointestinal Chagas is also empirical and is adapted to symptoms and signs of the pathology [7] . The hallmark of an epicardial posteroseptal accessory pathway is the presence of a steeply negative delta wave in lead II [1] [2] [3] . The delta wave in lead II was negative in our case, but not steeply negative. Nevertheless, an epicardial posteroseptal accessory pathway was ablation of accessory pathways [6] . The underlying mechanism is not well understood, and various mechanisms have been described.
In conclusion, even when the ECG does not suggest an epicardial pathway location in the coronary sinus, this possibility should be kept in mind in patients with posteroseptal accessory pathways. Especially when there is acute recovery of conduction after a successful initial ablation or resistance to ablation, coronary sinus diverticula should be searched for. Ablation within the coronary sinus is often performed using irrigated-tip ablation catheters; however, in our case, nonirrigated ablation successfully eliminated accessory pathway conduction.
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